Precision Biology solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics

News & Events

RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay
more →

RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing
more →

RareCyte® expands liquid biopsy offering with the release of a HER2/ER breast cancer CTC Panel Kit.
more →

Highlight

RareCyte expands its world-class liquid biopsy imaging and retrieval platform to support tissue workflows with the new CyteFinder II Instruments.

more →

RarePlex CTC Developer Staining Kit enables custom CTC assay development by providing the ability to add up to two biomarkers-of-interest to the CTC base detection assay.

more →

Pharma Programs

“The RareCyte CTC system has been analytically validated in our CAP/CLIA Laboratory and the validation and acceptance criteria met the needs of the clinical drug study team. In partnership with a global CRO, the CTC workflow is being successfully implemented.”

   – Jeff Fill, Senior Director, Diagnostic and Experimental Pathology, Eli Lilly and Company

more →